Short-acting GLP-1 receptor agonists include exenatide (Byetta, with limited US availability) and lixisenatide (Adlyxin, discontinued in the US market)
Molecular Structure and Properties# Retatrutide (LY3437943) is a synthetic peptide of approximately 39 amino acids, representing the first-in-class triple incretin receptor agonist
After 48 h, the cells were washed with PBS (Gibco) and incubated in the assay buffer (HBSS supplemented with Ca 2+ and Mg 2+ (Gibco), 10 mM HEPES (Gibco), 0.1% Pluronic F-68 (Gibco) and 500 M IBMX (Sigma), pH 7.4) with different concentrations of GLP-1 (0 M to 1 M) in the presence (100 nM and 1000 nM) or absence of Fab7F38 at 37 C for 30 min
On physical examination, observe for any erythema, swelling, ulceration, or contracture indicative of inflammation or necrosis
It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist Tirzepatide through a hybrid glucagon (GlucagonGcg) related structure, and is a drug for the treatment of obesity and type 2 diabetes
Not directly, but the mechanisms of GLP-1 therapy, including slowed gastric emptying and significantly reduced food intake, create conditions that increase B12 deficiency risk over time
.webp)
